Fractyl racks up $57 mln Series C
Waltham, Massachusetts-based Fractyl Laboratories Inc, which focuses on addressing metabolic diseases, has closed its Series C funding at $57 million. New investor Deerfield Management has joined Mithril, General Catalyst, Bessemer Venture Partners and Domain Associates in the round.
19 November 2015•3 mins read
